Tipranavir Patent Expiration
Tipranavir is Used for treating HIV-1 infection by co-administering tipranavir and ritonavir. It was first introduced by Boehringer Ingelheim Pharmaceuticals Inc
Tipranavir Patents
Given below is the list of patents protecting Tipranavir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Aptivus |
US6147095 (Pediatric) | Method for improving the pharmacokinetics of tipranavir |
Apr 29, 2020
(Expired) | Boehringer Ingelheim |
| Aptivus |
US5852195 (Pediatric) | Pyranone compounds useful to treat retroviral infections |
Dec 22, 2019
(Expired) | Boehringer Ingelheim |
| Aptivus | US6147095 | Method for improving the pharmacokinetics of tipranavir |
Oct 29, 2019
(Expired) | Boehringer Ingelheim |
| Aptivus | US5852195 | Pyranone compounds useful to treat retroviral infections |
Jun 22, 2019
(Expired) | Boehringer Ingelheim |
| Aptivus |
US6231887 (Pediatric) | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
Jan 27, 2019
(Expired) | Boehringer Ingelheim |
| Aptivus | US6231887 | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
Jul 27, 2018
(Expired) | Boehringer Ingelheim |
| Aptivus |
US6169181 (Pediatric) | Compounds useful to treat retroviral infections |
Nov 06, 2014
(Expired) | Boehringer Ingelheim |
| Aptivus | US6169181 | Compounds useful to treat retroviral infections |
May 06, 2014
(Expired) | Boehringer Ingelheim |
Tipranavir's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List